Immunome (NASDAQ:IMNM) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Immunome (NASDAQ:IMNM) from a strong sell rating to a sell rating in a research report released on Saturday,Wall Street Zen reports.

Several other research firms have also recently weighed in on IMNM. Alliance Global Partners started coverage on Immunome in a research report on Monday, September 21st. They set a “buy” rating and a $32.00 price objective for the company. Wedbush lifted their target price on Immunome from $31.00 to $35.00 and gave the company an “outperform” rating in a research report on Wednesday, August 12th. Citigroup restated a “buy” rating on shares of Immunome in a research note on Thursday, July 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a research report on Friday, July 17th. Finally, Truist Financial upped their price target on Immunome from $37.00 to $38.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Twelve research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Immunome currently has a consensus rating of “Moderate Buy” and an average target price of $35.18.

Immunome Trading Up 1.3%

IMNM opened at $21.68 on Friday. The stock has a market capitalization of $2.46 billion, a P/E ratio of -8.57 and a beta of 2.13. Immunome has a 12 month low of $11.09 and a 12 month high of $30.06. The firm’s fifty day simple moving average is $25.44 and its 200 day simple moving average is $22.86.

Immunome (NASDAQ:IMNM) last released its earnings results on Tuesday, August 11th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.14). On average, equities research analysts predict that Immunome will post -2.38 EPS for the current fiscal year.

Insider Buying and Selling at Immunome

In other news, insider Jack Higgins sold 13,200 shares of the firm’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $25.32, for a total value of $334,224.00. Following the completion of the transaction, the insider owned 65,050 shares in the company, valued at $1,647,066. This trade represents a 16.87% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Robert Lechleider sold 55,000 shares of Immunome stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $22.62, for a total value of $1,244,100.00. Following the completion of the sale, the insider directly owned 15,805 shares in the company, valued at approximately $357,509.10. This represents a 77.68% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 479,460 shares of company stock valued at $11,690,064. Corporate insiders own 7.21% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Allworth Financial LP bought a new stake in shares of Immunome during the 2nd quarter worth approximately $25,000. Integrated Wealth Concepts LLC bought a new position in shares of Immunome in the second quarter valued at $27,000. KBC Group NV bought a new position in shares of Immunome in the first quarter valued at $60,000. Assetmark Inc. increased its holdings in Immunome by 46.6% during the first quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock worth $99,000 after buying an additional 1,442 shares during the last quarter. Finally, State of Wyoming acquired a new position in Immunome during the second quarter worth $109,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based therapies for cancer and other serious diseases. The company uses proprietary antibody discovery and engineering technologies designed to identify therapeutic candidates from human immune responses and advance them into clinical development.

Immunome’s activities include the development of novel immunotherapies and targeted biologic medicines, with research programs aimed at addressing significant unmet needs in oncology and inflammatory or immune-mediated diseases.